HDFC Securities has come out with its third quarter (October-December) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Alkem Labs to report net profit at 210 crore down 27% quarter-on-quarter.
Net Sales are expected to decrease by 11.4 percent Q-o-Q (up 13.9 percent Y-o-Y) to Rs 1450 crore, according to HDFC Securities.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 20.5 percent Q-o-Q (up 4.9 percent Y-o-Y) to Rs 250 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
